Výsledky vyhledávání - "Melinda K. Lacy"

Time Course and Extent of Renal Function Changes in Patients Receiving Treatment for Staphylococcal Pneumonias: An Analysis Comparing Telavancin and Vancomycin from the ATTAIN Trials

Autor: Micah A. Jacobs, Boris Nogid, Melinda K. Lacy, Jamie P. Dwyer, Jon Bruss

Publikováno v: Pharmacotherapy

Study objective Telavancin and vancomycin are both approved for treatment of hospital-acquired and ventilator-associated bacterial pneumonias caused by Staphylococcus aureus, and both agents can cause renal dysfunction. The objective of this study wa

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::67e2cc031cae8f4ed1619a15a13fac97
https://doi.org/10.1002/phar.2165

Zobrazit plný text záznamu

2364. Evaluation of Renal Function Changes in Patients With Prolonged Telavancin Therapy (>21 Days): Results From the Telavancin Observational Use Registry (TOUR™)

Autor: Bibiana Castaneda-Ruiz, Chris N. Barnes, Vidya Sundareshan, Ali Hassoun, Melinda K. Lacy

Publikováno v: Open Forum Infectious Diseases

Background Telavancin (TLV) is a lipoglycopeptide antibacterial active against a wide range of Gram-positive organisms, including methicillin-susceptible and methicillin-resistant Staphylococcus aureus. New onset or worsening renal impairment was obs

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::914aa95ab4182c418e0c23a4ba1ae3c3
http://europepmc.org/articles/PMC6255214

Zobrazit plný text záznamu

Telavancin hospital-acquired pneumonia trials: impact of Gram-negative infections and inadequate Gram-negative coverage on clinical efficacy and all-cause mortality

Autor: G. Ralph Corey, Andrew F. Shorr, Melinda K. Lacy, Thomas C. Hardin, David R. Luke, Steven L. Barriere, Whedy Wang, Boris Nogid, Martin E. Stryjewski

Publikováno v: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 61

BACKGROUND When hospital-acquired or ventilator-associated bacterial pneumonia (HABP/VABP) is caused by gram-positive and gram-negative pathogens or both (mixed infections), the adequacy of gram-negative coverage (GNC) can confound the assessment of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eb34aa023829dbc0015b72b55f47a283
https://pubmed.ncbi.nlm.nih.gov/26316562

Zobrazit plný text záznamu

Nationwide Antibiogram Analysis Using NCCLS M39-A Guidelines

Autor: Dennis Grauer, Brian C. O’Neal, Rick Couldry, Melinda K. Lacy, Rebecca T. Horvat, Brian J. Barnes, Antonia Zapantis

Publikováno v: Journal of Clinical Microbiology. 43:2629-2634

Lack of standardization in antibiogram (ABGM) preparation (the overall profile of antimicrobial susceptibility results of a microbial species to a battery of antimicrobial agents) has not been addressed until recently. The objective of this study was

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b9276b0db8975b0054cafa8ab8438142
https://doi.org/10.1128/jcm.43.6.2629-2634.2005

Zobrazit plný text záznamu

Antibiograms: New NCCLS Guidelines, Development, and Clinical Application

Autor: Neil E. Klutman, Rebecca T. Horvat, Melinda K. Lacy, Antonia Zapantis

Publikováno v: Hospital Pharmacy. 39:542-553

Antibiograms are an important resource for health care providers. All clinicians involved in antibiotic selection and monitoring should become familiar with the NCCLS M39-A document “Analysis and Presentation of Cumulative Antimicrobial Susceptibil

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ce162f2e0c298ebfa9310aa786421ab5
https://doi.org/10.1177/001857870403900608

Zobrazit plný text záznamu

Clinical Experience with Telavancin for the Treatment of Patients with Bone and Joint Infections: Preliminary Results from the Telavancin Observational Use Registry (TOUR™)

Autor: Charles Sims, Anna Osmukhina, Bibiana Castaneda-Ruiz, Adam Bressler, Melinda K. Lacy

Publikováno v: Open Forum Infectious Diseases

Background Telavancin (TLV) is a lipoglycopeptide antibacterial active against a wide range of Gram-positive pathogens, including methicillin-sensitive and -resistant Staphylococcus aureus (MSSA and MRSA). Bone and joint infections represent a comple

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fc7c56c700687ac3a0409f7ac6ce6943
http://europepmc.org/articles/PMC5632217

Zobrazit plný text záznamu

Continuous versus intermittent administration of ceftazidime in intensive care unit patients with nosocomial pneumonia

Autor: David P. Nicolau, JoCarol McNabb, Melinda K. Lacy, Richard Quintiliani, Charles H. Nightingale

Publikováno v: International Journal of Antimicrobial Agents. 17:497-504

A prospective, randomized pilot study was undertaken to compare the efficacy of continuous versus intermittent ceftazidime in ICU patients with nosocomial pneumonia. Ceftazidime was administered either as a 3 g/day continuous infusion (CI) or an inte

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8d9a8982cc949e5ad7c3fcad0a2cdb7c
https://doi.org/10.1016/s0924-8579(01)00329-6

Zobrazit plný text záznamu

Moxifloxacin: Clinical efficacy and safety

Autor: Brian Edwards, Colleen M. Culley, Melinda K. Lacy, Neil E. Klutman

Publikováno v: American Journal of Health-System Pharmacy. 58:379-388

The activity, pharmacokinetics, pharmacodynamics, efficacy, safety, drug interactions, and dosage and administration of moxifloxacin are reviewed. Moxifloxacin is an oral 8-methoxyquinolone antimicrobial approved in December 1999 for use in the treat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::239d41123e825aeb16dd9cda594bce97
https://doi.org/10.1093/ajhp/58.5.379

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání